Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 71335-0262 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl713350262
This is a description of a medication named Losartan. It is a white, round 50mg tablet manufactured by Zhejiang Huahai Pharma Co Ltd. It is meant to be kept out of reach of children and stored at room temperature. The medication container should be stored at a temperature between 20°C and 25°C. The container contains thirty tablets and is marked with a specific expiration date and a National Drug Code of 7133502621 04238301523487.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This text shows the comparison between Atenolol and Losartan Potassium in terms of their effectiveness in reducing the risk of primary endpoint in patients. The results show that Losartan Potassium has an adjusted risk reduction of 13%, with a p-value of 0.021. The graph shows the study month timeline up to 66 months.*
Figure 2 - spl image3 figure2
This is a comparison between Atenolol and Losartan Potassium in reducing the risk of fatal or non-fatal stroke, where Losartan Potassium showed a 25% reduction in risk compared to Atenolol. The provided chart shows the percentage of patients with fatal or non-fatal stroke over a span of 66 study months.*
Figure 3 - spl image4 figure3
The text describes a table (Figure 3) showing the number of primary composite stroke events and hazard ratios for different subgroups (age, gender, race, ISH status, diabetes status, and history of CVD) in a study comparing the effectiveness of Losartan Potassium and Atenolol in preventing stroke. The table has symbols proportional to the sample size, and the results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. The text also includes a note explaining that "Other" category includes Asian, Hispanic, Asiatic, Multi-race, Indian, Native American, European.*
Figure 4 - spl image5 figure4
This is a chart showing the percentage of patients with event (presumably a medical event) over a period of 48 months. The data compares the effects of Losartan Potassium to Placebo. Losartan Potassium treatment has shown a 16.1% risk reduction in patients with events. The significance level of this result is p=0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.